Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
IRCCS Ospedale San Raffaele
Mayo Clinic
University of Alabama at Birmingham
Nationwide Children's Hospital
Mayo Clinic
Yale University
Tetragon Biosciences Ltd
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Beijing Bio-Targeting Therapeutics Technology Co., Ltd
Huashan Hospital
Azienda Sanitaria dell'Alto Adige
Coherence Neuro Australia Pty Limited
Washington University School of Medicine
NYU Langone Health
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Vanderbilt-Ingram Cancer Center
Case Comprehensive Cancer Center
The Cooper Health System
Assistance Publique - Hôpitaux de Paris
Cancer Research UK
M.D. Anderson Cancer Center
University of Alabama at Birmingham
Clinica Universidad de Navarra, Universidad de Navarra
VA Office of Research and Development
University of California, San Francisco
Hospital del Rio Hortega
Leica Microsystems (Schweiz) AG
Neonc Technologies, Inc.
Medical College of Wisconsin
Medical College of Wisconsin
Institut du Cancer de Montpellier - Val d'Aurelle
ImmVira Pharma Co. Ltd
Leica Microsystems (Schweiz) AG
NYU Langone Health
University of Zurich
Medical University Innsbruck
Philogen S.p.A.
Erasmus Medical Center
Nanjing First Hospital, Nanjing Medical University
Royal North Shore Hospital
Central Hospital, Nancy, France
Servier (Tianjin) Pharmaceutical Co. LTD.
Tanta University
Xijing Hospital
University College, London
University Hospital Regensburg
Institut National de la Santé Et de la Recherche Médicale, France
Suzhou Maximum Bio-tech Co., Ltd.
Istituto Clinico Humanitas